1,4-butanediol di-t-butyl ether | 82604-59-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,4-butanediol di-t-butyl ether
• 英文别名: 1,4-Di-tert-butoxybutane；1,4-bis[(2-methylpropan-2-yl)oxy]butane
• CAS: 82604-59-9
• 化学式: C₁₂H₂₆O₂
• 分子量: 202.337
• InChiKey: AWLBJSPDFPOVCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-tert-butyloxybutanol 、 叔丁醇 在 硫酸 、 magnesium sulfate 作用下， 反应 7.0h， 以8.3 g的产率得到1,4-butanediol di-t-butyl ether
  参考文献：
  名称：

  [EN] ETHER COMPOUNDS AS VOLATILES FOR THE TREATMENT OF AMINO ACID BASED SUBSTRATES, SUCH AS SKIN AND HAIR
  [FR] COMPOSÉS ÉTHER UTILISÉS COMME SUBSTANCES VOLATILES POUR LE TRAITEMENT DE SUBSTRATS À BASE D'ACIDES AMINÉS, TELS QUE LA PEAU ET LES CHEVEUX

  摘要：

  The present invention relates to a compound for use in cosmetic compositions of the formula (I): R1-O-R2, wherein R1and R2are different from each other and are independently selected from the group of C1-C17 hydrocarbyl residues, said hydrocarbyl residues contain up to 8 CH3groups and up to 3 ether groups (-O-), and wherein the total number of carbon atoms of said compounds is 10 to 20, the total number of ether groups of said compounds is 1 to 6, and the total number of methyl groups (-CH3) of said compounds is 1 to 13, at least one of R1and R2is a branched C3-C17 hydrocarbyl residue, in particular, as so-called volatiles in skin care and hair care compositions, as well as cosmetic compositions comprising at least one of said ether compounds, and the use of the aforementioned ether compounds in cosmetic compositions.

  公开号：

  WO2022152742A1

文献信息

• Acidic mixed oxide catalytic dealkylation to produce 1,4-butanediol and tetrahydrofuran
  申请人：GENERAL ELECTRIC COMPANY

  公开号：EP0124066A1

  公开（公告）日：1984-11-07

  A coproduct continuous dealkylation process is described in which 4-t-butoxy-n-butanol is contacted with acidic silica-alumina catalyst at temperatures in the 160-200°C range (reactor wall temperature) in the liquid hourly space velocity regime of 2:0 to 6:0 liter/liter catalyst/hr. to produce in a single reactor a mixture in which the ultimate product of conversion of the 4-t-butoxy-n-butanol is 1,4-butanediol (1,4-diol) and tetrahydrofuran (THF) present in a preselected ratio (mole %) of 1,4-diol to THF ranging from 7:3 to 3:7. The 1,4-diol produced is useful in the preparation of polyesters, e.g. polybutylene terephthalates, and THF is a useful intermediate in the manufacture of certain chemicals and plastics.

  描述了一种副产品连续脱烷基工艺，在该工艺中，4-t-丁氧基-正丁醇与酸性二氧化硅-氧化铝催化剂在 160-200°C 的温度范围内（反应器壁温）接触，在 2:0 至 6:0 升/升催化剂/小时的液体时空速度条件下，在单个反应器中生成混合物，其中 4-t-丁氧基-正丁醇的最终转化产物为 1,4-丁二醇（1,4-二醇）和四氢呋喃（THF）。在单个反应器中生成一种混合物，其中 4-叔丁氧基正丁醇的最终转化产物是 1,4-丁二醇（1,4-二醇）和四氢呋喃（THF），1,4-二醇和四氢呋喃的预选比例（摩尔百分比）为 7:3 至 3:7。生成的 1,4-二醇可用于制备聚酯，如聚对苯二甲酸丁二醇酯，而 THF 则是制造某些化学品和塑料的有用中间体。
• JPS60221428A
  申请人：——

  公开号：JPS60221428A

  公开（公告）日：1985-11-06
• QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS
  申请人：Gai Yonghua

  公开号：US20100003214A1

  公开（公告）日：2010-01-07

  The present invention discloses compounds of formula I and II or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• METHOD OF TREATING OR PREVENTING OSTEOPOROSIS COMPRISING ADMINISTERING TO A PATIENT IN NEED THEREOF AN EFFECTIVE AMOUNT OF PHARMACUETICAL COMPOSITION COMPRISING BENZAMIDINE DERIVATIVE OR IT'S SALT, AND BISPHOSPHONATE
  申请人：RYU Jei Man

  公开号：US20100029596A1

  公开（公告）日：2010-02-04

  The present invention provides a method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivative or its salt, and bisphosphonate for the purpose of using simultaneously, separately, or sequentially as active ingredients. As a prophylactic or therapeutic composition for osteoporosis, the combination treatment of the benzamidine derivative and the bisphosphonate compound exhibits excellent inhibitory effect on osteoclast differentiation than the total effect of each individual treatment, thereby being used for the prevention or treatment of osteoporosis.
• METHOD AND SYSTEM FOR PURIFICATION OF NATURAL GAS USING MEMBRANES
  申请人：Air Liquide Advanced Technologies U.S. LLC

  公开号：US20170157555A1

  公开（公告）日：2017-06-08

  Natural gas may be purified by removing C 3+ hydrocarbons and CO 2 in respective first and second gas separation membrane stages to yield conditioned gas lower in C 3+ hydrocarbons and CO 2 in comparison to the un-conditioned natural gas.